Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC).

Abstract

10623 Background: Single agent weekly docetaxel (D) is an active agent in the treatment of MBC with response rates of 29% - 53%. Erlotinib (OSI-774, Tarceva) is a tyrosine kinase inhibitor directed against the epidermal growth factor receptor (EGFR), and is overexpressed in 30-40% of breast cancers. EGFR inhibition by erlotinib (E) and its possible… (More)

Topics

Cite this paper

@article{Kaur2006ToxicityAO, title={Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC).}, author={Herlin Kaur and Paula Silverman and Deepjot Singh and B W Cooper and Pingfu Fu and Smitha S. Krishnamurthi and Scot C. Remick and Beth A. Overmoyer}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={10623} }